Karine Flem-Karlsen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Scientific reports

PloS one

Molecular cancer therapeutics

Oslo University Hospital

University of Oslo (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oslo University Hospital Sep 01 2017

Norway

PhD Candidate

Education History

University of Oslo Sep 01 2017

Norway

PHD :: Institute for Clinical Medicine

University of Oslo Aug 20 2013 - Dec 16 2015

Norway

MSC

University of Oslo Aug 20 2010 - Jun 20 2013

Norway

BSC

Publications

Goran Micevic, Andrew Daniels, Karine Flem-Karlsen, Koonam Park, Ronan Talty, Meaghan McGeary, Haris Mirza, Holly N Blackburn, Esen Sefik, Julie F Cheung, Noah I Hornick, Lilach Aizenbud, Nikhil S Joshi, Harriet Kluger, Akiko Iwasak, Marcus W Bosenberg, Richard A Flavell
IL-7R licenses a population of epigenetically poised memory CD8 + T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings of the National Academy of Sciences of the United States of America 120 (30) (2023)
Rahmad Akbar, Habib Bashour, Puneet Rawat, Philippe A Robert, Eva Smorodina, Tudor-Stefan Cotet, Karine Flem-Karlsen, Robert Frank, Brij Bhushan Mehta, Mai Ha Vu, Talip Zengin, José Gutiérrez Marcos, Fridtjof Lund-Johansen, Jan Terje Andersen, Victor Greiff
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. mAbs 14 (1) (2022)
Karine Flem-Karlsen, Marta Nyakas, Inger Nina Farstad, Erin McFadden, Patrik Wernhoff, Kari Dolven Jacobsen, Vivi Ann Flørenes, Gunhild Mari Mælandsmo
Soluble AXL as a marker of disease progression and survival in melanoma. PloS one 15 (1) (2020)
Karine Flem-Karlsen, Erin McFadden, Nasrin Omar, Mads Haugland Haugen, Geir Frode Øy, Truls Ryder, Hans Petter Gullestad, Robert Hermann, Gunhild Mari Mælandsmo, Vivi Ann Flørenes
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Molecular cancer therapeutics 19 (3) (2019)
Karine Flem-Karlsen, Christina Tekle, Tove Øyjord, Vivi A Flørenes, Gunhild M Mælandsmo, Øystein Fodstad, Caroline E Nunes-Xavier
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Scientific reports 9 (1) (2019)

Karine Flem-Karlsen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Karine Flem-Karlsen